Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1010904 ophthalmic suspension in Fuchs endothelial corneal dystrophy (Phase IIa)
2022-000174-25Phase 2Active
- Sponsor
- Santen Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in Fuchs endothelial dystrophy (FED) (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Primary Efficacy Endpoint. Started Aug 2022; status: active.
02
Drugs
sirolimus
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on 2022-000174-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000174-25.